A Phase 1/2, Single Arm Study to Assess the Efficacy and Safety of Rigosertib (ON 01910.Na) Administered as 72-Hour and 120-Hour Continuous Intravenous Infusions Every Other Week for Two Cycles Then as Twice-daily Oral Capsules Given Continuously in Patients with Relapsed/Refractory Acute Myeloid or Lymphocytic Leukemia or Transformed Myeloproliferative Neoplasms.

Trial Profile

A Phase 1/2, Single Arm Study to Assess the Efficacy and Safety of Rigosertib (ON 01910.Na) Administered as 72-Hour and 120-Hour Continuous Intravenous Infusions Every Other Week for Two Cycles Then as Twice-daily Oral Capsules Given Continuously in Patients with Relapsed/Refractory Acute Myeloid or Lymphocytic Leukemia or Transformed Myeloproliferative Neoplasms.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Rigosertib (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Onconova Therapeutics
  • Most Recent Events

    • 13 Nov 2014 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 31 Oct 2014 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center.
    • 05 May 2014 Planned End Date changed from 1 Jan 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top